Controlling the cost of innovative cancer therapeutics.
作者： Nafees N. Malik
DOI: 10.1038/NRCLINONC.2009.113
关键词: Cancer 、 Biotechnology 、 Drug pricing 、 Intensive care medicine 、 Biosimilar 、 Cancer drug discovery 、 Cancer drugs 、 Medicine 、 Health care 、 Drug discovery
摘要: … —government price controls on cancer drugs, biosimilars and novel drug pricing strategies. … in terms of their ability to reduce costs and their effect on innovative cancer drug discovery. …
nature.com
sci-hub.se 参考文章(5)
Joseph A. DiMasi, Henry G. Grabowski, The cost of biopharmaceutical R&D: is biotech different? Managerial and Decision Economics. ,vol. 28, pp. 469- 479 ,(2007) , 10.1002/MDE.1360
Peter B. Bach, Limits on Medicare's Ability to Control Rising Spending on Cancer Drugs The New England Journal of Medicine. ,vol. 360, pp. 626- 633 ,(2009) , 10.1056/NEJMHPR0807774
Carmelo Giaccotto, Rexford E. Santerre, John A. Vernon, Drug Prices and Research and Development Investment Behavior in the Pharmaceutical Industry The Journal of Law and Economics. ,vol. 48, pp. 195- 214 ,(2005) , 10.1086/426882
Melanie Williams, David Risser, Jon Hornaday, Elizabeth Sjoberg, Lynn Hancock, Brenda Mokry, Jessica Albano, Paul Betts, Mark Clanton, Karen B Heusinkveld, Mark Redrow, Allen Henderson, Lawrence S Frankel, Nancy S. Weiss, Lewis Foxhall, Cancer Facts & Figures 2004 ,(2004)
Patricia M. Danzon, Andrew Epstein, Sean Nicholson, Mergers and Acquisitions in the Pharmaceutical and Biotech Industries Managerial and Decision Economics. ,vol. 28, pp. 307- 328 ,(2007) , 10.1002/MDE.1343